keyword
MENU ▼
Read by QxMD icon Read
search

Ssri sexual dysfunction

keyword
https://www.readbyqxmd.com/read/29755571/plasma-oxytocin-level-and-sexual-dysfunction-in-depressed-women-treated-by-either-fluoxetine-or-citalopram-a-pilot-clinical-trial
#1
Mohammad Abbasinazari, Mona Heidari-Kord, Azadeh Mazaheri-Meybodi, Azadeh Eshraghi, Nima Bayati
Sexual dysfunction is a common cause of selective serotonin reuptake inhibitor (SSRI) withdrawal. Various studies indicate that decreased oxytocin is involved as a mechanism of delayed ejaculation induced by SSRIs. The aim of the present pilot study was to evaluate and compare sexual dysfunction and oxytocin levels in women being treated with either fluoxetine or citalopram. Thirty-nine women with the diagnosis of major depressive disorder were enrolled in the study. A baseline blood sample was collected and each participant was given either fluoxetine 20 mg/d or citalopram 20 mg/d...
2018: Iranian Journal of Pharmaceutical Research: IJPR
https://www.readbyqxmd.com/read/29733030/enduring-sexual-dysfunction-after-treatment-with-antidepressants-5%C3%AE-reductase-inhibitors-and-isotretinoin-300-cases
#2
David Healy, Joanna Le Noury, Derelie Mangin
OBJECTIVE: To investigate clinical reports of post-SSRI sexual dysfunction (PSSD), post-finasteride syndrome (PFS) and enduring sexual dysfunction following isotretinoin. METHODS: Data from RxISK.org, a global adverse event reporting website, have been used to establish the clinical features, demographic details and clinical trajectories of syndromes of persistent sexual difficulties following three superficially different treatment modalities.RESULTSWe report on 300 cases of enduring sexual dysfunction from 37 countries following 14 different drugs comprised of serotonin reuptake inhibiting antidepressants, 5α-reductase inhibitors and isotretinoin...
May 1, 2018: International Journal of Risk & Safety in Medicine
https://www.readbyqxmd.com/read/29675596/post-finasteride-syndrome-and-post-ssri-sexual-dysfunction-two-sides-of-the-same-coin
#3
REVIEW
Silvia Giatti, Silvia Diviccaro, Giancarlo Panzica, Roberto Cosimo Melcangi
Sexual dysfunction is a clinical condition due to different causes including the iatrogenic origin. For instance, it is well known that sexual dysfunction may occur in patients treated with antidepressants like selective serotonin reuptake inhibitors (SSRI). A similar side effect has been also reported during treatment with finasteride, an inhibitor of the enzyme 5alpha-reductase, for androgenetic alopecia. Interestingly, sexual dysfunction persists in both cases after drug discontinuation. These conditions have been named post-SSRI sexual dysfunction (PSSD) and post-finasteride syndrome (PFS)...
April 19, 2018: Endocrine
https://www.readbyqxmd.com/read/29463440/post-ssri-sexual-dysfunction-preclinical-to-clinical-is-it-fact-or-fiction
#4
REVIEW
Enis Rauf Coskuner, Mehmet Gokhan Culha, Burak Ozkan, Elcin Orhan Kaleagasi
INTRODUCTION: Selective serotonin reuptake inhibitors (SSRIs) are a widely used class of drug for various psychiatric disorders during the lifespan, including pregnancy, lactation, childhood, and adolescence. Deterioration in sexual functioning is a major and serious adverse effect of SSRIs. There is emerging evidence that SSRIs can have long-lasting effects on sexuality. AIM: To summarize the long-lasting effects of SSRIs on sexuality, starting with animal models and continuing with the clinical experience of different investigators...
April 2018: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/29403135/a-12-week-comparative-prospective-open-label-randomized-controlled-study-in-depression-patients-treated-with-vilazodone-and-escitalopram-in-a-tertiary-care-hospital-in-north-india
#5
Manish Bathla, Shazia Anjum, Manpreet Singh, Saminder Panchal, Gurvinder Pal Singh
Background: Depression is a leading cause of morbidity in modern world and introduction of selective serotonin reuptake inhibitors (SSRIs) was a revolution for treating depression. However, sexual dysfunction and weight gain always remained an issue for patients leading to discontinuation of treatment. Vilazodone is a novel SSRI and literature show better efficacy and decrease weight gain and sexual dysfunction. Aim of study: This study aims to compare the efficacy, sexual dysfunction, and weight gain caused due to vilazodone and escitalopram...
January 2018: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29355886/antidepressants-for-depression-in-adults-with-hiv-infection
#6
REVIEW
Ingrid Eshun-Wilson, Nandi Siegfried, Dickens H Akena, Dan J Stein, Ekwaro A Obuku, John A Joska
BACKGROUND: Rates of major depression among people living with HIV (PLWH) are substantially higher than those seen in the general population and this may adversely affect antiretroviral treatment outcomes. Several unique clinical and psychosocial factors may contribute to the development and persistence of depression in PLWH. Given these influences, it is unclear if antidepressant therapy is as effective for PLWH as the general population. OBJECTIVES: To assess the efficacy of antidepressant therapy for treatment of depression in PLWH...
January 22, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29238391/functional-impairment-and-painful-physical-symptoms-in-patients-with-major-depressive-disorder-treated-with-antidepressants-real-world-evidence-from-the-middle-east
#7
Jihyung Hong, Diego Novick, Maria Victoria Moneta, Ahmed El-Shafei, Héctor Dueñas, Josep Maria Haro
Background: The Global Burden of Disease 2010 study reported the relative size of major depressive disorder (MDD) burden to be greater in the Middle East and North Africa than anywhere else. However, little research has been carried out to examine the comparative effectiveness of antidepressants in this region. Objective: To assess and compare functioning levels in Middle Eastern patients with MDD treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI), and to examine the impacts of depression-related pain on functioning by the type of treatment...
2017: Clinical Practice and Epidemiology in Mental Health: CP & EMH
https://www.readbyqxmd.com/read/28679182/premature-ejaculation-pharmacotherapy-vs-group-psychotherapy-alone-or-in-combination
#8
RANDOMIZED CONTROLLED TRIAL
Carlo Pavone, Daniela Abbadessa, Giuseppa Gambino, Giovanna Scaduto, Marco Vella
OBJECTIVES: Premature Ejaculation (PE), the commonest sexual dysfunction in males, is generally treated with local anesthetic and SSRI (Dapoxetine). The aim of our study was investigate Group Psychotherapy as an alternative treatment for PE and compare the efficacy of pharmacological treatment and psychotherapy, either alone or in combination, in terms of response and improved Quality of Life (QoL). From a male outpatient population screened for PE, those who received a diagnosis of PE were proposed for the study, enrolled and divided into 3 groups (A, B and C)...
June 30, 2017: Archivio Italiano di Urologia, Andrologia
https://www.readbyqxmd.com/read/28663124/comparative-evaluation-of-vortioxetine-as-a-switch-therapy-in-patients-with-major-depressive-disorder
#9
RANDOMIZED CONTROLLED TRIAL
Michael E Thase, Natalya Danchenko, Melanie Brignone, Ioana Florea, Francoise Diamand, Paula L Jacobsen, Eduard Vieta
Switching antidepressant therapy is a recommended strategy for depressed patients who neither respond to nor tolerate an initial pharmacotherapy course. This paper reviews the efficacy and tolerability of switching to vortioxetine. All three published studies of patients with major depressive disorder (MDD) switched from SSRI/SNRI therapy to vortioxetine due to lack of efficacy or tolerability were selected. Vortioxetine was evaluated versus agomelatine directly (REVIVE) and versus sertraline, venlafaxine, bupropion, and citalopram in an indirect treatment comparison (ITC) from switch studies retrieved in a literature review...
August 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28642048/sexual-consequences-of-post-ssri-syndrome
#10
REVIEW
Yacov Reisman
INTRODUCTION: Sexual dysfunctions are well-known side effects of selective serotonin reuptake inhibitor (SSRI) use. Altered libido, erectile dysfunction, vaginal dryness, ejaculatory disorders, and orgasmic problems are frequently reported by patients treated with SSRIs. Moreover, these antidepressant-emergent sexual dysfunctions do not always resolve after discontinuation of the medication and can persist indefinitely. These complaints are termed post-SSRI sexual dysfunctions (PSSD)...
October 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/28289796/-neurobiological-foundations-underlying-normal-and-disturbed-sexuality
#11
REVIEW
T H C Krüger, J Kneer
BACKGROUND: Sexual functions are regulated by hormonal and neurochemical factors as well as neuronal networks. An understanding of these basic principles is necessary for the diagnostics, counselling and treatment of sexual problems. OBJECTIVE: Description of essential mechanisms of sexual function on a neurochemical and neuronal level. MATERIAL AND METHODS: Literature search, selection and discussion of relevant studies. RESULTS: Analogous to the dual control model there are primary inhibitory (e...
May 2017: Der Nervenarzt
https://www.readbyqxmd.com/read/28129308/comparison-of-the-efficacy-and-safety-of-aripiprazole-versus-bupropion-augmentation-in-patients-with-major-depressive-disorder-unresponsive-to-selective-serotonin-reuptake-inhibitors-a-randomized-prospective-open-label-study
#12
RANDOMIZED CONTROLLED TRIAL
Eun-Jin Cheon, Kwang-Hun Lee, Young-Woo Park, Jong-Hun Lee, Bon-Hoon Koo, Seung-Jae Lee, Hyung-Mo Sung
PURPOSE: The purpose of this study was to compare the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder (MDD) unresponsive to selective serotonin reuptake inhibitors (SSRIs). METHODS: This is the first randomized, prospective, open-label, direct comparison study between aripiprazole and bupropion augmentation. Participants had at least moderately severe depressive symptoms after 4 weeks or more of SSRI treatment...
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28025939/serotonin-selective-reuptake-inhibitors-ssris-and-female-sexual-dysfunction-fsd-hypothesis-on-its-association-and-options-of-treatment
#13
Nurul Azmi Mahamad Rappek, Hatta Sidi, Jaya Kumar, Sazlina Kamarazaman, Srijit Das, Ruziana Masiran, Najwa Baharudin, Muhammad Hatta
Sexual dysfunctions are commonly seen in women on selective serotonin reuptake inhibitors (SSRIs). The complexities of female sexual functioning are reflected through modulation of inter-playing factors like the neuropsychophysiological factors, inter-personal and relationship issue, psychiatric co-morbidities and physical disorder. The incidence of SSRIs-induced FSD is difficult to estimate because of the potentially confounding effects of SSRIs, presence of polypharmacy, marital effect, socio-cultural factors and due to the design and assessment problems in majority of the studies...
December 27, 2016: Current Drug Targets
https://www.readbyqxmd.com/read/27701952/add-on-mirtazapine-improves-orgasmic-functioning-in-patients-with-schizophrenia-treated-with-first-generation-antipsychotics
#14
Viacheslav Terevnikov, Jan-Henry Stenberg, Jari Tiihonen, Mark Burkin, Grigori Joffe
AIM: Sexual dysfunction, common in schizophrenia, may be further exaggerated by antipsychotics, especially those of First Generation (FGAs), and antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRs). Mirtazapine, an antidepressant characterized by its different action mechanism compared with that of the majority of other antidepressants, may improve SSRI-induced sexual dysfunction in patients with depression. It is unknown, however, whether mirtazapine improves sexual functioning in schizophrenia...
January 2017: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/27652223/is-there-a-place-for-surgical-treatment-of-premature-ejaculation
#15
REVIEW
Du Geon Moon
Management of premature ejaculation (PE) has evolved tremandoulsy over the last 20 years. Selective serotonin reuptake inhibitor (SSRI) antidepressants and local anesthetics are the most and best studied treatments. This evidence has led to the establishment of an evidence-based definition of PE and the International Society for Sexual Medicine (ISSM) guidelines for the diagnosis and treatment of PE. The current treatment of choice for PE according to the ISSM guidelines is a centrally acting SSRI or peripherally acting topical anesthetics...
August 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/27456527/efficacy-and-safety-of-dapoxetine-in-treatment-of-premature-ejaculation-an-evidence-based-review
#16
REVIEW
A Russo, P Capogrosso, E Ventimiglia, G La Croce, L Boeri, F Montorsi, A Salonia
BACKGROUND: Premature ejaculation (PE) is a major issue in male sexual health, with a global prevalence estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a negative impact on interpersonal relationships. Historically, it has been treated with cognitive therapy, behavioural methods and off-label use of selective serotonin reuptake inhibitors (SSRIs) usually used to treat depression and other psychological disorders...
September 2016: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/27423475/-antidepressant-and-tolerance-determinants-and-management-of-major-side-effects
#17
REVIEW
D J David, D Gourion
Antidepressant therapy aims to reach remission of depressive symptoms while reducing the complications and risks of relapse. Even though they have proven their efficacy, it takes several weeks for antidepressants to demonstrate full effectiveness, and adverse effects occur more quickly or (quicker) which can be a source of poor compliance. This latest aspect often leads to dose reduction and/or change of molecule that have the effect of delaying remission. This review attempts to present, from the pharmacological properties of the major classes of antidepressants (monoamine oxidase inhibitor [MAOI], tricyclic antidepressants [TCA], selective serotonin reuptake inhibitor [SSRI] and serotonin and noradrenaline reuptake inhibitor [SNRI]), to the pharmacological mechanisms involved in adverse effects by focusing on sexual dysfunction, nausea/vomiting, and weight changes and sleep disruption...
December 2016: L'Encéphale
https://www.readbyqxmd.com/read/27413150/serotonin-and-antidepressant-ssris-inhibit-rat-neuroendocrine-dopamine-neurons-parallel-actions-in-the-lactotrophic-axis
#18
David J Lyons, Rachida Ammari, Arash Hellysaz, Christian Broberger
UNLABELLED: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression, but sexual side effects often compromise compliance. These reproductive dysfunctions are likely mediated by elevations of the hormone prolactin. Yet, how serotonin (5-HT) and SSRIs cause changes in prolactin secretion is not known. Here, using in vitro whole-cell patch-clamp recordings, we show that 5-HT hyperpolarizes and abolishes phasic discharge in rat neuroendocrine tuberoinfundibular dopamine (TIDA) neurons, the main inhibitor of prolactin secretion...
July 13, 2016: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/27392437/fluoxetine-and-the-mitochondria-a-review-of-the-toxicological-aspects
#19
REVIEW
Marcos Roberto de Oliveira
Fluoxetine (a selective serotonin reuptake inhibitor (SSRI)) is used as an antidepressant by modulating the levels of serotonin in the synaptic cleft. Nevertheless, fluoxetine also induces undesirable effects, such as anxiety, sexual dysfunction, sleep disturbances, and gastrointestinal impairments. Fluoxetine has been viewed as an agent that may interfere with cell fate by triggering apoptosis. On the other hand, fluoxetine intake has been associated with increased cancer risk. Nonetheless, data remain contradictory and no conclusions were taken...
September 6, 2016: Toxicology Letters
https://www.readbyqxmd.com/read/27176752/persistent-sexual-dysfunction-after-early-exposure-to-ssris-systematic-review-of-animal-studies
#20
REVIEW
Anders Lykkemark Simonsen, Pia Brandt Danborg, Peter Christian Gøtzsche
BACKGROUND: Sexual dysfunction is a common adverse effect of selective serotonin reuptake inhibitors (SSRIs) and there is a concern that the sexual harms might persist after discontinuation of therapy. OBJECTIVE: To assess whether the use of SSRIs in animals can lead to persistent sexual dysfunction. METHODS: Systematic review of animal studies measuring sexual behaviour after end of treatment with SSRIs or serotonin norepinephrine reuptake inhibitors...
March 16, 2016: International Journal of Risk & Safety in Medicine
keyword
keyword
96683
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"